

**TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER**  
**INSTITUTIONAL BIOSAFETY COMMITTEE (IBC)**

**M I N U T E S**

Tuesday, 06/10/2025 1:02 PM  
Zoom

**Confidential Medical Document:** This meeting agenda is intended for the sole use of the intended recipient(s) and contains confidential and privileged information. Unauthorized review, disclosure or distribution is prohibited.

<b>MEETING ATTENDANCE</b>
---------------------------

**Voting members present:** Abraham Al-Ahmad, PhD, Israel Chapa, Velvetlee Finckbone, MS, RLAT, Shayla Ford, BS, RN, Petar Grozdanov, PhD, Armando Hernandez, Aveline Hewetson, PhD, Magdalena Karbowniczek, MD, PhD, Byron Lara, Albert Patton III, BS, Stephen R Perez, Dana Marie Telesford, PhD

**Voting members absent:** Sharilyn Almodovar, PhD, Xiaodong Cheng, MD, PhD, Cassie Kruczek, PhD, Malaiyalam Mariappan, PhD, Jyotsna Sharma, PhD, Scott Trasti, DVM

**Guests present:** Brian Pellam (Safety Services) from TTUHSC, Toni Denison, MS, CPHQ

**Administrative staff present:** Zachary Clark, MSHA

**Ex officio present:** Karlie Kennon

<b>OLD BUSINESS</b>
---------------------

Minutes for the May meeting were approved as written. The following members abstained as they were not present during the May meeting: Velvetlee Finckbone, MS, RLAT, Magdalena Karbowniczek, MD, PhD, Byron Lara, Dana Marie Telesford, PhD

<b>INITIAL SUBMISSIONS</b>
----------------------------

IBC #	25006	Expires: 06/30/2026	Ref: 095257	BSL: 2	Risk Group: 2
PI:	Beth Wright, PhD				
Title:	Cooper Center Longitudinal Study Biobank				
Review Item:	Submission Correction for Initial Review Submission				
Training:	All required trainings have been completed.				
NIH Guidelines:	Not Applicable				
Outcome:	Approved				

<b>3-YEAR RENEWALS</b>
------------------------

IBC #	16012	Expires: 06/30/2025	Ref: 095253	BSL: 2	Risk Group: 2
PI:	Andrey L Karamyshev, PhD				
Title:	Institutional Biosafety Committee (r/s Nucleic Acid Research: EXEMPT)				
Review Item:	IBC Protocol 3-Year Renewal				
Training:	All required trainings have been completed.				
NIH Guidelines:	Section III-D-1				
Outcome:	pending modifications (Post-Meeting FCR)				
Stipulations:	1. 3.1. Please check the "generate aerosol" box. 2. The BSOP Plasmid is almost entirely incomplete, starting with Section 2.2.				

IBC #	19002	Expires: 06/30/2026	Ref: 095276	BSL: 2	Risk Group: 2
PI:	Igor Ponomarev, PhD				

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: Exempt)  
Review Item: Submission Correction for IBC Protocol 3-Year Renewal  
Training: All required trainings have been completed.  
NIH Guidelines: Section III-D-4  
Outcome: Approved

IBC # 01013 Expires: 06/30/2026 Ref: 095266 BSL: 2 Risk Group: 2  
PI: Afzal Siddiqui, PhD  
Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: NON-EXEMPT)  
Review Item: IBC Protocol 3-Year Renewal  
Training: All required trainings have been completed.  
NIH Guidelines: Section III-D-4, III-D-2  
Outcome: Approved

IBC # 10011 Expires: 06/30/2026 Ref: 095255 BSL: 2 Risk Group: 2  
PI: Minghai Wang, MD, PhD  
Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: EXEMPT) The RON receptor in cancer malignancy and its potential as the target for cancer therapy  
Review Item: Submission Correction for IBC Protocol 3-Year Renewal  
Training: All required trainings have been completed.  
NIH Guidelines: Section III-F  
Outcome: Approved

<b>FULL COMMITTEE REVIEW AMENDMENTS</b>
---

N/A

<b>DESIGNATED MEMBER REVIEW</b>
---------------------------------

IBC # 25003 Expires: 03/31/2026 Ref: 095267 BSL: 2 Risk Group: 2  
PI: Aric Logsdon, PhD  
Title: Exploring Mechanisms of Neurobehavioral Dysfunction using Traumatic Brain Injury Models  
Review Item: Submission Correction for IBC Protocol Amendment Form  
Training: All required trainings have been completed.  
NIH Guidelines: Section III-F  
Outcome: agent and location change; Approved

IBC # 24004 Expires: 09/30/2025 Ref: 095292 BSL: 2 Risk Group: 2  
PI: Malaiyalam Mariappan, PhD  
Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: Exempt)  
Review Item: Submission Correction for IBC Protocol Amendment Form  
Training: All required trainings have been completed.  
NIH Guidelines: Section III-D-3  
Outcome: agent change; Approved

IBC # 25005 Expires: 06/30/2026 Ref: 095186 BSL: 2 Risk Group: 2  
PI: Mark Sigler, MD  
Title: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in

Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations

Review Item: Submission Correction for Initial Review Submission

Training: N/A

NIH Guidelines: Not Applicable

Outcome: pending (administrative)

Stipulations: Pending completion of trainings.

IBC # 23006 Expires: 08/31/2025 Ref: 094540 BSL: 2 Risk Group: 2

PI: Hongmin Wang, PhD

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: Exempt)

Review Item: Submission Correction for IBC Protocol Amendment Form

Training: All required trainings have been completed.

NIH Guidelines: Section III-F

Outcome: agent and personnel change; Approved

#### ANNUAL STATUS REPORTS

IBC # 05013 Expires: 06/30/2026 Ref: 095251 BSL: 2 Risk Group: 2

PI: Jannette Dufour, PhD

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: NON-EXEMPT)

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Section III-E, III-D-3

Outcome: Approved Administratively

IBC # 17004 Expires: 06/30/2026 Ref: 095252 BSL: 2 Risk Group: 2

PI: Ronald Hall, PharmD

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: not applicable)

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Not Applicable

Outcome: personnel change; Approved Administratively

IBC # 14007 Expires: 06/30/2026 Ref: 095248 BSL: 2 Risk Group: 2

PI: Volker Neugebauer, MD, PhD

Title: Institutional Biosafety Committee

Review Item: IBC Annual Status Report

Training: All required trainings have been completed.

NIH Guidelines: Section III-D-4

Outcome: Personnel change; Approved Administratively

#### ADMINISTRATIVE AMENDMENTS

IBC # 23008 Expires: 01/31/2026 Ref: 095298 BSL: 2 Risk Group: 2

PI: Boris Decourt, PhD

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: Not Applicable)

Review Item: IBC Protocol Amendment Form

Training: All required trainings have been completed.

NIH Guidelines: Section III-F

Outcome: personnel change; Approved Administratively

IBC # 05013 Expires: 06/30/2026 Ref: 095278 BSL: 2 Risk Group: 2

PI: Jannette Dufour, PhD

Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: NON-EXEMPT)

Review Item: IBC Protocol Amendment Form

Training: All required trainings have been completed.  
NIH Guidelines: Section III-E, III-D-3  
Outcome: location change; Approved Administratively

IBC # 11001 Expires: 09/30/2025 Ref: 095296 BSL: 2 Risk Group: 2  
PI: Magdalena Karbowiczek, MD, PhD  
Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: NON-EXEMPT)  
Review Item: IBC Protocol Amendment Form  
Training: All required trainings have been completed.  
NIH Guidelines: Section III-D-4, Section III-D-3  
Outcome: personnel change; Approved Administratively

IBC # 25003 Expires: 03/31/2026 Ref: 095260 BSL: 2 Risk Group: 2  
PI: Aric Logsdon, PhD  
Title: Exploring Mechanisms of Neurobehavioral Dysfunction using Traumatic Brain Injury Models  
Review Item: IBC Protocol Amendment Form  
Training: All required trainings have been completed.  
NIH Guidelines: Section III-F  
Outcome: add personnel; Approved Administratively

IBC # 23005 Expires: 07/31/2025 Ref: 095305 BSL: 2 Risk Group: 2  
PI: Samuel Obeng, PhD  
Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: Exempt)  
Review Item: IBC Protocol Amendment Form  
Training: All required trainings have been completed.  
NIH Guidelines: Section III-D-1  
Outcome: remove personnel; Approved Administratively

IBC # 23005 Expires: 07/31/2025 Ref: 095271 BSL: 2 Risk Group: 2  
PI: Samuel Obeng, PhD  
Title: Institutional Biosafety Committee (r/s Nucleic Acid Research: Exempt)  
Review Item: IBC Protocol Amendment Form  
Training: All required trainings have been completed.  
NIH Guidelines: Section III-D-1  
Outcome: add personnel; Approved Administratively

#### TERMINATIONS

N/A

#### WITHDRAWALS

N/A

#### BSO REPORTS

Lab Inspections for June.

#### CLOSING COMMENTS

Discussions regarding the minutes and S.B. 1488.

#### ADJOURNMENT

1:48 PM

\* Individual(s) with conflict of interest stepped out during vote.